Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADORING 3: Long-term extension of tapinarof cream for atopic dermatitis
NCT05142774Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Oct 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of tapinarof in atopic dermatitis (AD), sponsored by Organon & Co. Primary endpoints: Treatment-Emergent Adverse Events at 49 weeks, Change From Baseline in Clinical Laboratory Values at 48 weeks and 10 more. Started Oct 2021; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05142774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142774.